Skip to main content
TEVA logo

TEVA · Teva Pharmaceutical Industries Ltd · Investor Relations

Track TEVA — free
$42.62 +0.05 (+0.12%) At close · Nov 17 Play latest call Q3 2026 earnings call transcript
Market Cap
$49.73B
Shares
1.17B
Volume · Nov 17 7.02M Avg daily vol (3M) 6.16M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-16 U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
2026-11-11 Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
2026-11-03 Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
2026-11-03 Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
2026-11-02 Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
2026-10-27 Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
2026-10-20 UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
2026-10-12 Teva to Host R&D Day on Wednesday, November 11 in New York City
2026-10-09 Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
2026-10-02 Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
2026-10-02 Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
2026-10-01 Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
2026-09-30 TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
2026-09-28 Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
2026-09-23 Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
2026-09-23 Teva Releases Q3 2026 Aide Memoire
2026-09-18 New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
2026-09-18 Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
2026-09-18 Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
2026-09-16 Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
2026-09-14 Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
2026-09-10 Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
2026-09-07 Teva Announces Launch of Offering of Senior Notes
2026-09-04 S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
2026-09-02 Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Past events

Date Event Type
2026-11-11 Teva R&D Day Webcast
2026-11-03 Q3 2026 Teva Pharmaceutical Industries Ltd. Earnings Conference Call Earnings call
2026-10-09 WELTRUZA™ (olanzapine) Approval – Conference Call Conference
2026-09-23 BofA Global Healthcare Conference 2026 Conference
2026-09-22 JPM U.S. All Stars Conference Conference
2026-09-22 J.P. Morgan U.S. All Stars Conference Conference
2026-09-14 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-09-02 IL-15 Celiac Disease Phase 2a Topline Results - Conference Call Earnings call
2026-07-29 Q2 2026 Teva Pharmaceutical Industries Ltd. Earnings Conference Call Earnings call
2026-07-07 IL-15 Vitiligo Phase 1b 24 Week Efficacy Results - Conference Call Earnings call
2026-06-08 Goldman Sachs Global Healthcare Conference Conference
2026-05-12 BofA Securities Health Care Conference Conference
2026-04-29 Q1 2026 Teva Pharmaceutical Industries Ltd. Earnings Conference Call Earnings call
2026-04-29 Q1 2026 Earnings Call Earnings call
2026-03-10 Barclays 28th Annual Global Healthcare Conference Conference
2026-03-09 Leerink Partners Global Healthcare Conference Conference
2026-03-03 UBS European Healthcare Conference Conference
2026-02-17 Duvakitug IBD Ph2b Maintenance Top-Line Result Webcast
2026-01-28 Q4 2025 Teva Pharmaceutical Industries Ltd. Earnings Conference Call Earnings call
2026-01-13 44th Annual J.P. Morgan Healthcare Conference Conference
2025-12-04 Citi's 2025 Global Healthcare Conference Conference
2025-12-03 Piper Sandler 37th Annual Healthcare Conference Conference
2025-12-03 8th Annual Evercore Healthcare Conference Conference
2025-11-18 Jefferies London Healthcare Conference Conference
2025-11-10 UBS Global Healthcare Conference Conference

Source: https://ir.tevapharm.com/

Key facts CIK 818686 CUSIP M8769Q102 13F (30d) 628 filings 563 filers Visit website Investor relations